HOME > TOP STORIES

TOP STORIES

BUSINESS Generic Market Continues to Grow, Three Generic-Only Makers’ Sales Up 8.8%

November 13, 2013
BUSINESS GLP-1 Dulaglutide “Catalyst of Growth,” SGLT-2 Empagliflozin Will Be Successful Despite Later Launch: Lilly Diabetes President

November 12, 2013
BUSINESS 4 Major Wholesalers’ Operating Margins Stay on Recovery Path, But Average Settlement Rate at Mere 72% at Sept.-End

November 11, 2013
BUSINESS Nichi-Iko Pitting Allegra AG against Other Generics, Not Originator: Pres. Tamura

November 8, 2013
REGULATORY “Precursor Premium” Proposed at CSIMC Drug Pricing Subcommittee, Yet Further Deliberations Necessary

November 7, 2013
REGULATORY Chairman Eto of LDP’s Study Group on Drug Industry Policy Calls for “Balance” in Discussions of Special Price Cuts for Long-Listed Drugs

November 7, 2013
BUSINESS Japan ARB Market Gets Back on Growth Track in April-September; No Major Impact from Diovan Woes

November 6, 2013
ORGANIZATION Drug Damage Watchdog Presses Criminal Charge against Novartis over Diovan Ads

November 5, 2013
ACADEMIA Subordinate of Former Employee of Novartis Pharma Participated in SMART Study; Protocol Violations Also Found

November 5, 2013
ACADEMIA Mismatch Found for 10% of ACR Data Between Papers, Patient Records: SMART Study

November 1, 2013
BUSINESS Takeda 1st Half Sales Rise 5.3% on New Portfolio, Weaker Yen

November 1, 2013
REGULATORY New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium

October 31, 2013
ORGANIZATION PhRMA Makes Yet Another Case for Perpetuation of New Drug Premium

October 31, 2013
REGULATORY Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo

October 30, 2013
REGULATORY 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment

October 30, 2013
ACADEMIA Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL

October 29, 2013
ORGANIZATION Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March

October 28, 2013
BUSINESS Teva’s Global Medical Director Says Biosimilars Can Cut Medical Costs

October 25, 2013
REGULATORY Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28

October 25, 2013
REGULATORY Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member

October 24, 2013

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…